학술논문
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
Document Type
article
Author
Christina Rautenberg; Friedrich Stölzel; Christoph Röllig; Matthias Stelljes; Verena Gaidzik; Michael Lauseker; Oliver Kriege; Mareike Verbeek; Julia Marie Unglaub; Felicitas Thol; Stefan W. Krause; Mathias Hänel; Charlotte Neuerburg; Vladan Vucinic; Christian-Friedrich Jehn; Julia Severmann; Maxi Wass; Lars Fransecky; Jens Chemnitz; Udo Holtick; Kerstin Schäfer-Eckart; Josephine Schröder; Sabrina Kraus; William Krüger; Ulrich Kaiser; Sebastian Scholl; Kathrin Koch; Lea Henning; Guido Kobbe; Rainer Haas; Nael Alakel; Maximilian-Alexander Röhnert; Katja Sockel; Maher Hanoun; Uwe Platzbecker; Tobias A. W. Holderried; Anke Morgner; Michael Heuser; Tim Sauer; Katharina S. Götze; Eva Wagner-Drouet; Konstanze Döhner; Hartmut Döhner; Christoph Schliemann; Johannes Schetelig; Martin Bornhäuser; Ulrich Germing; Thomas Schroeder; Jan Moritz Middeke
Source
Blood Cancer Journal, Vol 11, Iss 10, Pp 1-8 (2021)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26–80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available information achieving measurable residual disease (MRD) negativity (